Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

Yaohui Ji brings nearly two decades of leadership experience as BioDuro strengthens its integrated contract research, development, and manufacturing organization (CRDMO) platform for small and large molecule development.

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

In a review of CPHI Frankfurt 2025, several event exhibitors chat about the trends making waves in the industry and highlight the importance of face-to-face collaborations and networking.

Given the current complexities and challenges facing large molecule biomanufacturing, senior leaders believe it is imperative for industry to redefine the rules of competition, improve innovation, and be more intelligently connected.

There are a variety of challenges facing the small molecule drug sector, from U.S. tariff challenges and regulatory uncertainty to the demands of latest wave of complexity, meaning that CDMOs must act as proactive strategic partners.

The CDMO has completed the expansion of its Pessano facility in Milan, Italy, adding increased packaging and warehousing capacity that has already been authorized by the AIFA and is producing validation and commercial batches.

Primary packaging requirements are evolving in line with development trends; however, flexible and easily integrated ready-to-use solutions are beneficial options, highlight Dr. Robert Lindner and Christoph Zauner from SCHOTT Pharma.

For Jacob Werlinger from Bend Bioscience, turning innovative concepts into reality requires CDMOs to not just be service providers but more of a strategic scientific partner that can help advance the concept to commercialization using the right science tools.

Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses Laura Chirica from Cellevate.  

As geopolitical factors are driving a greater focus on U.S. manufacturing, many companies are seeking ways to improve productivity while keeping their products affordable for patients, highlights Russel Miller from Enzene.

Innovation is driving OSD into new frontiers, from orally delivered biologics and enhanced solubility to sustainable manufacturing and AI-driven formulation development, asserts Shahrzad Missaghi from Colorcon.

For Timothy Compton from Alcami, there are numerous trends driving the surge in demand for U.S. based bio/pharma manufacturing, including the benefits of a greater quality culture and adaptability to batch size requirements.

CDMOs need to be more than just providers of capacity, they need to be integrated strategic solution partners, embedding flexibility, reliability, and sustainability into their business models, according to Dr. Max Lauwiner from Valsynthese.

Having a partner involved from the outset of a sterile fill/finish project to help plan and support at each stage, is a potentially beneficial approach for innovators, highlights Hanns-Christian Mahler from ten23 health.

Increasingly complex and moisture-sensitive ingredients require careful, considered, and connected approaches that ensure the integrity of the finished product is maintained, explains Christian Classen from Sanner Group.

This year’s show, taking place in Frankfurt, Germany, has grown further incorporating representation from the whole bio/pharma supply chain and providing networking opportunities for a global audience, reveals Tara Dougal, Event Director.

According to Kevin Li from BioDuro, bio/pharma partnerships are most successful when the parties involved are aligned, operating as one team with mutual trust and long-term vision.

It is possible to achieve longer-acting injectable drug products that also do not require aseptic fill/finish thanks to a new advanced drug delivery system, reveals Mårten Rooth from Nanexa.